๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed or Refractory Lymphomas

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study NCT05846763n/a1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites๐Ÿ“ Chicago๐Ÿ“ Evanston๐Ÿ“ Providence AvenCell Therapeutics, Inc. ยท Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917NA1 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: JY231 Injection Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: C7R.CD30.CAR-EBVST cells Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL NCT07074470NA1 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor), Consolidation therapy with ASCโ€ฆ Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Xynomic Pharmaceuticals, Inc. ยท Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites๐Ÿ“ Denver๐Ÿ“ Atlanta๐Ÿ“ Fairway Verismo Therapeutics ยท Tests: SynKIR-310 CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Autologous CAR19 T lymphocytes Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CD5-targeted CAR-T cells Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma NCT07439653Phase 1, Phase 29 sites๐Ÿ“ Fullerton๐Ÿ“ Los Alamitos๐Ÿ“ Santa Monica TORL Biotherapeutics, LLC ยท Tests: TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL NCT05552937Phase 21 site๐Ÿ“ Hangzhou Beijing InnoCare Pharma Tech Co., Ltd. ยท Tests: Tafasitamab and Lenalidomide Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib GVMยฑR in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: GVMยฑR regimen Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites๐Ÿ“ Duarte๐Ÿ“ Chicago๐Ÿ“ New York AIDS Malignancy Consortium ยท Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma NCT06377540Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Pembrolizumab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: tislezumab, golidocitinib, Selinexor Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Atlanta Andrew E. Place, MD ยท Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478Phase 2131 sites๐Ÿ“ Chandler๐Ÿ“ Duarte๐Ÿ“ Irvine Loxo Oncology, Inc. ยท Tests: Pirtobrutinib CD45BE-HSPC + CART-45 Cells NCT07451054Phase 11 site๐Ÿ“ Philadelphia University of Pennsylvania ยท Tests: CART-45 cells, CD45BE-HSPC Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site๐Ÿ“ Milan Incyte Biosciences Italy S.r.l A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) NCT07072169Phase 11 site๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: ABO2203 Injection A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) NCT06207123Phase 1, Phase 22 sites๐Ÿ“ Chicago๐Ÿ“ Rochester University of Chicago ยท Tests: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: CAR-T Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia NCT07133997Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL NCT06855823Phase 1, Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Golicitinib combined with Pomadomide Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ Columbus๐Ÿ“ Richmond Yazeed Sawalha ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ฮถ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) NCT03938987Phase 1, Phase 26 sites๐Ÿ“ Calgary๐Ÿ“ Calgary๐Ÿ“ Calgary University of Alberta ยท Tests: autologous CD19-directed chimeric antigen receptor (CAR) T-cells
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy